A bipartisan Senate bill dubbed the “Skinny Label, Big Savings Act” was introduced in January. The bill would expand the scope of protection afforded by section viii carve-outs, a mechanism that allows Abbreviated New Drug...more
3/4/2025
/ Abbreviated New Drug Application (ANDA) ,
Biosimilars ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
New Legislation ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry
Amarin sells the drug icosapent ethyl under the brand name Vascepa. Vascepa is approved by the FDA for two indications: (i) to treat severe hypertriglyceridemia, a condition characterized by blood triglyceride levels greater...more